Precision health is the future. At Parallel, we aim to unlock precision skin health through genomics paired with microbial formulations that are efficacious, sustainable, and beautiful.Natalise Kalea Robinson, CEO
- Natalise Kalea Robinson, MBA
- Nathan Brown, PhD
- When we invested
- Crista Galli LABS
- Personalised medicine
What we do
With our proprietary data set, we are establishing the gold standard for skin microbiome types, assessing consumers’ needs based on their types and creating precision formulations with targeted microbes. Our goal is to manipulate the skin microbiome for optimized health, enabling the consumer to be proactive about prevention and treatment with clean, clinical-grade solutions.
Using cutting-edge genomic technology, we are unlocking the skin microbiome and empowering people with targeted, microbial solutions.
- DATA: We have amassed a proprietary data set with key insights on the skin microbiome, as well as personalization
- PLATFORM: Our bacterial library and product engine consists of >10,000 bacterial strains for future use
- IP: we have filed a provisional patent, using targeted microbial formulations for issue-causing bacterial overgrowths